CoChat

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

Open access
Hunter, Kerry, Hölscher, Christian · 2012 · BMC Neuroscience

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for AD. Liraglutide (Victoza) and exenatide (Byetta) are novel long-lasting analogues of the GLP-1 incretin hormone and are currently available to treat diabetes. They facilitate insulin signalling via the GLP-1 receptor (GLP-1R). Numerous in vitro and in vivo studies have shown that GLP-1 analogues have a range of neuroprotective properties. GLP-1Rs are expressed in the hippocampal area of the brain an important site of adult neurogenesis and maintenance of cognition and memory formation. Therefore, if GLP-1 analogues can cross the blood brain barrier, diffuse through the brain to reach the receptors and most importantly activate them, their neuroprotective effects may be realized. RESULTS: In the present study we profiled the GLP-1 receptor agonists liraglutide (Victoza) and lixisenatide (Lyxumia). We measured the kinetics of crossing the blood brain barrier (BBB), activation of the GLP-1R by measuring cAMP levels, and physiological effects in the brain on neuronal stem cell proliferation and neurogenesis. Both drugs were able to cross the BBB. Lixisenatide crossed the BBB at all doses tested (2.5, 25, or 250 nmol/kg bw ip.) when measured 30 min post-injection and at 2.5-25 nmol/kg bw ip. 3 h post-injection. Lixisenatide also enhanced neurogenesis in the brain. Liraglutide crossed the BBB at 25 and 250 nmol/kg ip. but no increase was detectable at 2.5 nmol/kg ip. 30 min post-injection, and at 250 nmol/kg ip. at 3 h post-injection. Liraglutide and lixisenatide enhanced cAMP levels in the brain, with lixisenatide being more effective. CONCLUSIONS: Our results suggest that these novel incretin analogues cross the BBB and show physiological activity and neurogenesis in the brain, which may be of use as a treatment of neurodegenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2202-13-33

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 At 5 min post- ip. injection, there was no significant increase of liraglutide in the brains of mice (A). There was an increase in liraglutide levels in the brains of mice injected with 25 or 250 nmol/kg bw at 30 min (B) and only those injected with the highest dose at 3 h post-injection (C). Brain levels of cAMP were increased 30 min post injection with 25 nmol/kg bw ip.. * = p < 0.05. Values are the mean ± S.E.M.
Figure 1 At 5 min post- ip. injection, there was no significant increase of liraglutide in the brains of mice (A). There was an increase in liraglutide levels in the brains of mice injected with 25 or 250 nmol/kg bw at 30 min (B) and only those injected with the highest dose at 3 h post-injection (C). Brain levels of cAMP were increased 30 min post injection with 25 nmol/kg bw ip.. * = p < 0.05. Values are the mean ± S.E.M.CC BY · PubMed Central
Figure 2 (A) Lixisenatide levels in the brains at 30 min following i.p. (2.5, 25 or 250 nmol/kg body weight) injection were increased. (B) Lixisenatide levels in the brains at 3 h following i.p. injection were only increased for the lower doses (2.5, 25 nmol/kg body weight). (C) The number of neuronal progenitor cells in the dentate gyrus was increased after 3 weeks of ip injection 25 nmol/kg bw once-daily. (D) The number of young neurons in the dentate gyrus was also increased. (E) The level of cAMP was enhanced in the brains after injection with 25 nmol/kg bw ip. (F) When directly comparing the effects of liraglutide with lixisenatide, a significant difference between drugs is found.* = p < 0.05, ** = p < 0.01. Micrographs: BrdU stain: A Saline control B Lixisenatide treated, 3 weeks once daily i.p. injection. Blue arrows point to BrdU positively stained cells. DCX stain: Doublecortin stained immature neurons in dentate gyrus. A Saline control B Lixisenatide treated, 3 weeks once daily i.p. administration.
Figure 2 (A) Lixisenatide levels in the brains at 30 min following i.p. (2.5, 25 or 250 nmol/kg body weight) injection were increased. (B) Lixisenatide levels in the brains at 3 h following i.p. injection were only increased for the lower doses (2.5, 25 nmol/kg body weight). (C) The number of neuronal progenitor cells in the dentate gyrus was increased after 3 weeks of ip injection 25 nmol/kg bw once-daily. (D) The number of young neurons in the dentate gyrus was also increased. (E) The level of cAMP was enhanced in the brains after injection with 25 nmol/kg bw ip. (F) When directly comparing the effects of liraglutide with lixisenatide, a significant difference between drugs is found.* = p < 0.05, ** = p < 0.01. Micrographs: BrdU stain: A Saline control B Lixisenatide treated, 3 weeks once daily i.p. injection. Blue arrows point to BrdU positively stained cells. DCX stain: Doublecortin stained immature neurons in dentate gyrus. A Saline control B Lixisenatide treated, 3 weeks once daily i.p. administration.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 504

Metadata

Authors
Hunter, K., & Hölscher, C.
Affiliations
University of Ulster (GB)
Corresponding author
Hölscher, Christian
Venue
BMC Neuroscience
Published
2012-03-23
Volume
13
Issue
1
Pages
33-33
ISSN
1471-2202 (ISSN-L)
OpenAlex
W2065372294
Cited by
504
References
23
Citations by year
2026: 26 · 2025: 54 · 2024: 40 · 2023: 37 · 2022: 32 · 2021: 32 · 2020: 38 · 2019: 28 · 2018: 40 · 2017: 34 · 2016: 37 · 2015: 37 · 2014: 39 · 2013: 22 · 2012: 8
FWCI
22.74
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lancaster EPrints (Lancaster University) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
Keywords
liraglutide, lixisenatide, exenatide, GLP-1 receptor agonists, blood-brain barrier penetration, neurogenesis, cAMP signaling, insulin signaling, Alzheimer's disease, type 2 diabetes, neuroprotection, hippocampus
MeSH terms
Glucagon-Like Peptide-2 Receptor, Liraglutide, Animals, Blood-Brain Barrier, Brain, Dose-Response Relationship, Drug, Female, Hypoglycemic Agents, Neurons, Peptides, Mice, Glucagon-Like Peptide 1, Neurogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. https://app.cochat.ai/papers/10.1186/1471-2202-13-33
The paper
Hunter, K., & Hölscher, C. (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neuroscience. https://doi.org/10.1186/1471-2202-13-33

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.